Ass.-Prof. Dr. Florian Kopp

 Contact

 

Mail: florian.kopp @ univie.ac.at

Telephone: +43 1 4277 555 81

Fax: +43 1 4277 9551

Room: 2E450

Publications

  1. Elguindy MM, Kopp F, Goodarzi M, Rehfeld F, Thomas A, Chang TC, Mendell JT. PUMILIO, but Not RBMX, Binding Is Required for Regulation of Genomic Stability by Noncoding RNA NORAD. eLife. 2019. http://doi.org/10.7554/eLife.48625
  2. Kopp F. Molecular functions and biological roles of long non‐coding RNAs in human physiology and disease. J. Gene Med. 2019. https://doi.org/10.1002/jgm.3104
  3. Kopp F, Elguindy MM, Yalvac ME, Zhang H, Chen B, Gillett FA, Lee S, Sivakumar S, Yu H, Xie Y, Mishra P, Sahenk Z, Mendell JT. PUMILIO Hyperactivity Drives Premature Aging of Norad-deficient Mice. eLife. 2019. http://doi.org/10.7554/eLife.42650
  4. Kopp F, Mendell JT. Functional Classification and Experimental Dissection of Long Noncoding RNAs. Cell 2018. http://doi.org/10.1016/j.cell.2018.01.011
  5. Golden RJ, Chen B, Li T, Braun J, Manjunath H, Chen X, Wu J, Schmid V, Chang TC, Kopp F, Ramirez-Martinez A, Tagliabracci VS, Chen ZJ, Xie Y, Mendell JT. An Argonaute Phosphorylation Cycle Promotes microRNA-mediated Silencing. Nature. 2017. http://doi.org/10.1038/nature21025
  6. Lee S, Kopp F, Chang TC, Sataluri A, Chen B, Sivakumar S, Yu H, Xie Y, Mendell JT. Noncoding RNA NORAD Regulates Genomic Stability by Sequestering PUMILIO Proteins. Cell. 2016. http://doi.org/10.1016/j.cell.2015.12.017
  7. Kopp F, Hermawan A, Oak PS, Ulaganathan VK, Herrmann A, Elnikhely N, Thakur C, Xiao Z, Knyazev P, Ataseven B, Savai R, Wagner E, Roidl A. Sequential Salinomycin Treatment Results in Resistance Formation Through Clonal Selection of Epithelial-Like Tumor Cells. Transl. Oncol. 2014. http://doi.org/10.1016/j.tranon.2014.09.002
  8. Kopp F, Wagner E, Roidl A. The Proto-Oncogene KRAS Is Targeted by miR-200c. Oncotarget. 2014. http://doi.org/10.18632/oncotarget.1427
  9. Kopp F, Hermawan A, Oak PS, Herrmann A, Wagner E, Roidl A. Salinomycin Treatment Reduces Metastatic Tumor Burden by Hampering Cancer Cell Migration. Mol. Cancer. 2014. http://doi.org/10.1186/1476-4598-13-16
  10. Kopp F, Schnoedt M, Haase R, Wagner E, Roidl A, Ogris M. De-targeting by miR-143 Decreases Unwanted Transgene Expression in Non-Tumorigenic Cells. Gene Therapy. 2013. http://doi.org/10.1038/gt.2013.37
  11. Haase R, Magnusson T, Su B, Kopp F, Wagner E, Lipps H, Baiker A, Ogris M. Generation of a tumor- and tissue-specific episomal non-viral vector system. BMC Biotechnol. 2013. http://doi.org/10.1186/1472-6750-13-49
  12. Oak PS, Kopp F, Thakur C, Ellwart JW, Rapp UR, Ullrich A, Wagner E, Knyazev P, Roidl A. Combinatorial Treatment of Mammospheres With Trastuzumab and Salinomycin Efficiently Targets HER2-positive Cancer Cells and Cancer Stem Cells. Int. J. Cancer. 2012. http://doi.org/10.1002/ijc.27595
  13. Kopp F, Oak PS, Wagner E, Roidl A. miR-200c Sensitizes Breast Cancer Cells to Doxorubicin Treatment by Decreasing TrkB and Bmi1 Expression. PLoS One. 2012. http://doi.org/10.1371/journal.pone.0050469